Tajikistan Humanitarian Aid and Rare Disease Imports: Registration Fee Exemption Rules

1. Key takeaways

In Tajik law, the only fee exemption clause with a clear legal source for registration fees is Article 17(11) of Law No. 1893: medicines used for the diagnosis and treatment of rare diseases, as well as medicines and medical devices imported into the Republic of Tajikistan as humanitarian aid and used in the implementation of state health programs, are exempt from registration fees. GRZAN highlights two points. First, apart from this provision, Law No. 1893 sets no specific fee amounts and no other exemption situations for registration; the various fee figures circulating on public channels are all practical estimates. Second, humanitarian aid supplies carry a separate shelf-life threshold under Article 24, together with liability provisions for misappropriation and sale that make the exemption conditional on strict use control.

2. Legal basis

3. Expert insights

Insight 1: Article 17(11) is the only express legal text citable on registration fees in Tajikistan. Law No. 1893 names the rule-making bodies for conformity assessment service fees under Article 13(2) and for quality certificate service fees under Article 9(4), but gives no amounts; for registration fees it provides only one exemption in paragraph 11. GRZAN’s operating principle is that any external statement about Tajik registration fees cites only Article 17(11), while every other figure is labeled a practical estimate and confirmed against the official payment notice before it enters any budget or client proposal.

Insight 2: the exemption of Article 17(11) covers two categories, and only the second expressly includes medical devices. The first category is medicines used for the diagnosis and treatment of rare diseases, expressed as medicines; the second category is medicines and medical devices imported as humanitarian aid and used in state health programs. This distinction matters greatly to device companies: a device can seek the fee exemption only through the humanitarian aid pathway, because the rare disease pathway does not apply to devices on the face of the text, even where a device serves the diagnosis of a rare condition.

Insight 3: the shelf-life threshold of Article 24(2) is a hard indicator, and the calculation method is a common trap. For medicines with a shelf life of less than one year, the remaining shelf life must be not less than 50 percent; for those exceeding one year, not less than 10 months. The key concept is the remaining shelf life, measured at the time the goods arrive, not the nominal shelf life at production. GRZAN recommends planning production and shipment backwards from the expected arrival date in Tajikistan and reserving time for inspection and customs clearance, because delays in transit silently erode the remaining shelf life below the threshold.

Insight 4: Article 24(3) ties the misappropriation and sale of aid supplies directly to legal liability. Natural persons and legal persons are liable under Tajik legislation for misappropriating or selling medicines and medical devices intended for humanitarian purposes. This follows the same legislative logic as Article 17(4)(7), which covers exhibition samples that may not be sold onward: the exemption rests on a strictly limited use, and once the use boundary is crossed, the consequence is administrative or even heavier liability, extending potentially to the foreign donor and the local partner alike.

Insight 5: the humanitarian aid pathway and the simplified registration route are two independent benefit lines. The simplified route of Article 17(9) applies to situations of military action, emergencies and outbreaks of epidemics, while the fee exemption of Article 17(11) applies to rare disease medicines and humanitarian aid. The applicable situations and the legal effects differ, so the two should be assessed separately and applied for separately, never treated as a single combined relief mechanism in project planning.

4. Practical recommendations

1. Treat Article 17(11) as the only citable legal provision in fee modeling. GRZAN recommends listing this provision alone as the statutory exemption item in internal fee templates, with every other fee line labeled a practical estimate and confirmed against the official payment notice.
2. Use the humanitarian aid pathway for device companies. Under the second category of Article 17(11), devices imported with humanitarian aid supplies may apply for the fee exemption; prepare the aid documents, the mapping to the state health program and the supply list in advance.
3. Plan aid production and shipment backwards from the arrival date. Under Article 24(2), calculate from the expected arrival date in Tajikistan so the remaining shelf life meets the 50 percent or 10 months threshold, and reserve time for inspection and customs clearance.
4. Keep a full usage record for aid supplies. Under Article 24(3), maintain a complete ledger from entry into the country to final use, covering the receiving institution, usage records and the disposal of any surplus, so that any inspection can be answered with documentation.
5. Keep the humanitarian aid line and the simplified registration line separate. In the project evaluation form, record Article 17(9) and Article 17(11) as two independent fields, each with its own applicable basis, so the two benefit lines are never mixed in one application.

5. Verification checklist

• □ Confirmed that Article 17(11) is the only registration fee exemption clause with a legal source in Tajikistan
• □ Distinguished the first category of paragraph 11, rare disease medicines, from the second category, medicines and medical devices imported as humanitarian aid
• □ Prepared the humanitarian aid documents and the proof of mapping to the state health program
• □ Planned aid production and shipment backwards from the arrival date to meet the 50 percent or 10 months threshold of Article 24(2)
• □ Built a full usage ledger for aid supplies from entry to final use under Article 24(3)
• □ Listed Article 17(11) as the only statutory exemption item in internal fee templates, with other lines marked as practical estimates
• □ Kept Article 17(9) and Article 17(11) as separate benefit lines in the project evaluation form

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a dual-track choice exists between the national route and the Union route; Uzbekistan is an observer state with only a national route; Tajikistan and Turkmenistan sit outside the Union framework and must follow purely national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries and undertakes registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com